

International Journal of
Endocrine Oncology

Welcome to Volume 7 of the *International Journal of Endocrine Oncology*

Lauren Woolfe*,¹

¹Future Science Group, Unitec House, 2 Albert Place, London, N3 1QB, UK

*Author for correspondence: l.woolfe@future-science.com

“Working on the *International Journal of Endocrine Oncology* this past year has been fantastic, and we have some exciting plans for 2020.”

First draft submitted: 10 January 2020; Accepted for publication: 10 January 2020; Published online: 14 February 2020

Happy New year and welcome to Volume 7 of *International Journal of Endocrine Oncology*. As the new Editor of the journal, I am extremely excited to work on new projects and ideas for 2020, as well as working with our excellent authors, peer reviewers and editorial board members.

Content highlights of 2019

International Journal of Endocrine Oncology publishes four issues per year, each filled with a variety of articles of high standard and interest.

A personal highlight was the two-part interview with leading endocrine oncologist Dr. Gary Hammer (Rogel Cancer Center, MA, USA). In Part 1, Hammer discussed the current research currently underway in his lab at the University of Michigan, as well as the development and current challenges in diagnosis and management of endocrine neoplasia [1]. Hammer also shared a personal story surrounding the development of the company Millendo Therapeutics. In Part 2, Hammer explained how the University of Michigan developed the leading endocrine neoplasia group, alongside the importance of patient advocacy and global engagement for rare diseases [2]. These Interviews are well worth a read and have the highest number of downloads within the first month of publication for 2019.

Another fantastic article was an editorial on bronchial carcinoids, written by Dan Granberg (Uppsala University, Sweden) [3]. In the article, he explains how these neuroendocrine tumor symptoms, pathology, diagnosis and treatment vary, as well as providing alternative treatment options, and explaining the need for the development of novel therapeutics.

Finally, we have a brilliant case report – one of our top three most-read articles of 2019 – entitled ‘Familial paraganglioma due to a novel SDHB mutation: familial phenotypic heterogeneity and a potentially novel manifestation’ written by researchers from King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia [4]. This case report provides in-depth clinical diagnosis and management of a patient with Familial paraganglioma with primary hyperparathyroidism – a combination not well described in the literature. The authors highlight the importance of lifelong surveillance with this novel SDHA mutation due to the variability in phenotypic presentations and heterogeneity

Article outreach

The majority of the *International Journal of Endocrine Oncology* readers are from the Americas (37%), Europe (31%) and Asia (29%) (Figure 1). We are continuing our work on harnessing the power of social media to disseminate our high-quality research and aim to reach all relevant stakeholders in the endocrine oncology space.

If you do not already, we welcome you to follow us on twitter (@fsgije) as well as subscribe to our partnered website Oncology Central [5], to keep up to date with the latest research and news.

Future
Medicine




Figure 1. Reader demographics 2019.

Editorial Board

International Journal of Endocrine Oncology would also like to thank its Editorial Board for its continued support, which has enabled 2019 to be an amazing year. We would also like to say a special thank you to our Senior Editors Electron Kebebew and Karel Pacak (both of the National Cancer Institute, MD, USA) for their hard work in 2019 and continued guidance for the year to come.

If you would like to learn more about what our Editorial Board members do or how to get involved, please do not hesitate to get in touch. We are always on the lookout for more experts in such a diverse space as endocrine oncology.

Conclusion

Working on the *International Journal of Endocrine Oncology* this past year has been fantastic, and we have some exciting plans for 2020. If you have any ideas for the journal, be it an outline for an article or a theme for an issue, we would love to hear it so please get in touch.

Once again thank you to our readers, authors, peer reviewers and Editorial Board members for all of their hard work and support throughout 2019 – we look forward to working together in 2020.

Financial & competing interest disclosure

L Woolfe is an employee of Future Science Ltd. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Open access

This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>

References

1. Hammer G. An interview with Gary D Hammer, MD, PhD. *Int. J. Endo. Oncol.* 6(4), IJE23 (2019).
2. Hammer G. Gary D Hammer on the improvement of patient care in endocrine neoplasia. *Int. J. Endo. Oncol.* 6(4), IJE24 (2019).
3. Granberg D. Bronchial carcinoids. *Int. J. Endo. Oncol.* 6(1), IJE16 (2019).
4. Alzahrani A, Alswailem M, Albattal S, Qasem E, Murugan A, Al-Hindi A. Familial paraganglioma due to a novel SDHB mutation: familial phenotypic heterogeneity and a potentially novel manifestation. *Int. J. Endo. Oncol.* 6(1), IJE12 (2019).
5. Oncology Central (2019). www.oncology-central.com/